search
Back to results

Thrombectomy in Patients Ineligible for iv tPA (THRILL)

Primary Purpose

Ischemic Stroke

Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Thrombectomy
Best medical care
Sponsored by
University Hospital Heidelberg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemic Stroke focused on measuring Cerebral Stroke, Stroke, Acute, Brain Infarction

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is ineligible for treatment with IV tPA according to licensing criteria (e.g.

anticoagulation, previous surgery, or beyond 4.5 hours after symptom onset).

  • Randomization within 7 hours after stroke onset.
  • Endovascular treatment is expected to be finished within 8 hours after symptom onset by judgment of the interventional Neuroradiologist in charge.
  • Patient must demonstrate clinical signs and symptoms attributable to target area of occlusion consistent with the diagnosis of ischemic stroke, including impairment of the following: language, motor function, sensation, cognition, gaze, and/or vision for at least 30 minutes without relevant improvement.
  • Female and male patient between 18-80 years of age
  • NIHSS Score of >7 and <25
  • Patient signed informed consent (IC) form by patient, legal representative, or by an independent physician who is familiar with this types of illness if the other options are not possible.
  • A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or the intracranial segment of the distal internal carotid artery (ICA).
  • Prior to new focal neurological deficit, mRS score was ≤1.

Exclusion Criteria:

  • Patient is eligible for and receives IV tPA according to licensing criteria
  • Patient with an international normalized ratio (INR) of >3
  • Patient is an active participant in another drug or device treatment trial for any disease state, or patient is expected to start participation in another drug or device treatment trial while enrolled in this protocol, unless approved by Sponsor.
  • Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations.
  • Patient has carotid dissection, high grade stenosis ≥ 70% proximal to occlusion that requires stenting, or excessive tortuosity to gain access to occlusion, as determined by MRA/ CTA of neck and head.
  • Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access)
  • Patient has history of contraindication for contrast medium.
  • Patient is known to have infective endocarditis
  • CT scan or MRI with evidence of: Mass effect or intracranial tumor, or hypodensity on unenhanced CT and cerebral blood volume (CBV) drop on CBV maps on Computed Tomography Perfusion (CTP), or, alternatively as per institutional standard, restricted diffusion on Diffusion weighted imaging (DWI) with an Alberta Stroke Program Early CT score (ASPECTs) of 6 or less
  • Female of childbearing potential who is known to be pregnant and/or lactating or who has a positive pregnancy test on admission.
  • Patient"s anticipated life expectancy is less than 6 Months.

Sites / Locations

  • Institut für Radiologie Oö. Gesundheits- und Spitals-AG Landes-Nervenklinik Wagner-Jauregg
  • Klinik für Diagnostische und Interventionelle Neuroradiologie Universitätsklinikum Aachen
  • Klinische und interventionelle Neuroradiologie Vivantes Klinikum Neukölln
  • Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin Universitätsklinikum Knappschaftskrankenhaus Bochum
  • University Clinic Bochum
  • Kinik für Radiologie und Neuroradiologie
  • Abteilung für Neuroradiologie Universitätsklinikum Erlangen
  • Klinik für Radiologie und Neuroradiologie Alfried Krupp Krankenhaus
  • Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie Universitätsklinikum Essen
  • Klinik für Neuroradiologie Universitätsklinikum Freiburg
  • Institut für Diagnostische & Interventionelle Neuroradiologie Universitätsmedizin Göttingen
  • Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention
  • Asklepios Klinik Altona
  • Universität Heidelberg, Neuroradiologie
  • Diagnostik , Neuroradiologie, Universitätsklinikum Köln
  • Abteilung für Neuroradiologie Klinikum der Universität München Campus
  • Abteilung für Diagnostische & Interventionelle Neuroradiogie Klinikum rechts der Isar der TU München
  • Klinik für Radiologie, Neuroradiologie und Nuklearmedizin Behandlungszentrum Knappschaftskrankenhaus Recklinghausen
  • Abteilung für Neuroradiologie Universitätsklinikum Würzburg

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Best medical care

Thrombectomy

Arm Description

Best clinical care in dedicated stroke unit

All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).

Outcomes

Primary Outcome Measures

mRS Shift
The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days poststroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days postprocedure between treatment groups ("mRS shift analysis"). The null and alternative hypotheses are β ≥ 0 and β < 0, respectively, where β is the treatment arm parameter in a proportional-odds logistic model with mRS category as response variable.

Secondary Outcome Measures

Neurological outcome
Good neurological outcome with 90-day modified rankin Scale (mRS) ≤2 Good neurological outcome with 90-day NIHSS (National Institutes of Health Stroke Scale) improvement ≥10 from baseline Excellent neurological outcomes with 90-day mRS≤1
Health Status
Functional health status and quality of life 90 (±14) days after stroke (EQ-5D)
Infarct volume
Infarct volume at 30 (-/+ 6) hours based on Computer Tomography or Magnetic Resonance Imaging compare to predicted infarct volume at time of patients hospital admission.
Successful Recanalization
For the endovascular treatment group successful recanalization will be defined as Thrombolysis in Cerebral Infarction scale (TICI) 2b or 3.

Full Information

First Posted
April 30, 2014
Last Updated
June 5, 2018
Sponsor
University Hospital Heidelberg
Collaborators
University Hospital, Aachen, University Hospital Augsburg, Vivantes Krankenhaus Berlin Neukölln, Ruhr University of Bochum, Klinikum Dortmund Wirbelsäulenchirurgie, University of Erlangen-Nürnberg Medical School, Alfried Krupp Krankenhaus, University Hospital, Essen, University Hospital Freiburg, University Medical Center Goettingen, Universitätsklinikum Hamburg-Eppendorf, Universitätsklinik für Neurologie, Innsbruck, Universitätsklinikum Köln, The Wagner-Jauregg Provincial Neuropsychiatric Clinic, LMU Klinikum, Klinikum rechst der Isar Technische Universitaet Muenchen, KLINIKUM VEST Recklinghausen, Wuerzburg University Hospital, Asklepios Kliniken Hamburg GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT02135926
Brief Title
Thrombectomy in Patients Ineligible for iv tPA
Acronym
THRILL
Official Title
Comparison of Thrombectomy and Standard Care for Ischemic Stroke in Patients Ineligibility for Tissue Plasminogen Activator Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Terminated
Why Stopped
Results from other RCT made randomization unethical.
Study Start Date
March 2014 (undefined)
Primary Completion Date
February 1, 2017 (Actual)
Study Completion Date
February 1, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Heidelberg
Collaborators
University Hospital, Aachen, University Hospital Augsburg, Vivantes Krankenhaus Berlin Neukölln, Ruhr University of Bochum, Klinikum Dortmund Wirbelsäulenchirurgie, University of Erlangen-Nürnberg Medical School, Alfried Krupp Krankenhaus, University Hospital, Essen, University Hospital Freiburg, University Medical Center Goettingen, Universitätsklinikum Hamburg-Eppendorf, Universitätsklinik für Neurologie, Innsbruck, Universitätsklinikum Köln, The Wagner-Jauregg Provincial Neuropsychiatric Clinic, LMU Klinikum, Klinikum rechst der Isar Technische Universitaet Muenchen, KLINIKUM VEST Recklinghausen, Wuerzburg University Hospital, Asklepios Kliniken Hamburg GmbH

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
the purpose of this study is to to compare the safety and effectiveness of stent-retrievers as a device class group with best medical care alone in the treatment of acute ischemic stroke (AIS) in patients who are not eligible for IV-tPA up to 8 hours of symptom onset.
Detailed Description
This is a prospective, binational (Germany and Austria), two-arm, randomized, controlled, open label, blinded endpoint post-market study to compare the safety and effectiveness of stent retrievers for thrombectomy compared to best medical treatment alone in acute ischemic stroke (AIS) patients not eligible for IV-tPA treatment. Patients who meet the inclusion criteria will be randomized to one of the following two treatment arms: best medical care alone or best medical care plus endovascular thrombectomy with stent retriever (referred to as thrombectomy). Endpoints in this prospective open label study will be assessed blinded to the treatment assignment of the patient (PROBE design). This study will be conducted in up to 20 centers in Germany and Austria. This is an adaptive design study, in which there are prospectively stated interim analyses with specified stopping rules, which allow for the possibility of the study to terminate early based on either a determination of study success or of the futility to continue further enrollment. Up to six hundred (600) subjects, 300 per treatment group, will be enrolled and randomized in the study for the Intent to Treat (ITT) analysis set. The randomization will be stratified by time from symptom onset and stroke severity (NIHSS). The expected duration of each subject"s enrollment is approximately 90 days. Subjects will be followed with assessments at 30 (+/-6) hours, hospital discharge, and 90 (+/-14) days post stroke. A blinded core laboratory will assess baseline imaging to confirm vessel occlusion and determine ASPECT score, 30 (+/- 6) hours post treatment imaging to assess presence of ICH, and to measure core infarct volume. The primary effectiveness endpoint for a subject is the blinded evaluation of the ordinal mRS outcome at 90 days post-stroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in mRS outcomes at 90 days post-stroke between treatment groups ("mRS shift analysis").

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke
Keywords
Cerebral Stroke, Stroke, Acute, Brain Infarction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Best medical care
Arm Type
Active Comparator
Arm Description
Best clinical care in dedicated stroke unit
Arm Title
Thrombectomy
Arm Type
Active Comparator
Arm Description
All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
Intervention Type
Device
Intervention Name(s)
Thrombectomy
Other Intervention Name(s)
Stent Retrievers, Solitaire (Covidien), Trevo (Stryker)
Intervention Description
Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
Intervention Type
Other
Intervention Name(s)
Best medical care
Other Intervention Name(s)
clinical care, conservative treatment
Intervention Description
Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
Primary Outcome Measure Information:
Title
mRS Shift
Description
The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days poststroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days postprocedure between treatment groups ("mRS shift analysis"). The null and alternative hypotheses are β ≥ 0 and β < 0, respectively, where β is the treatment arm parameter in a proportional-odds logistic model with mRS category as response variable.
Time Frame
90 (+/-14) days after treatment
Secondary Outcome Measure Information:
Title
Neurological outcome
Description
Good neurological outcome with 90-day modified rankin Scale (mRS) ≤2 Good neurological outcome with 90-day NIHSS (National Institutes of Health Stroke Scale) improvement ≥10 from baseline Excellent neurological outcomes with 90-day mRS≤1
Time Frame
90 (+/- 14) days after treatment
Title
Health Status
Description
Functional health status and quality of life 90 (±14) days after stroke (EQ-5D)
Time Frame
90 (+/-14) days after treatment
Title
Infarct volume
Description
Infarct volume at 30 (-/+ 6) hours based on Computer Tomography or Magnetic Resonance Imaging compare to predicted infarct volume at time of patients hospital admission.
Time Frame
30 (-/+ 6) hours after treatment
Title
Successful Recanalization
Description
For the endovascular treatment group successful recanalization will be defined as Thrombolysis in Cerebral Infarction scale (TICI) 2b or 3.
Time Frame
30 (-/+ 6) hours after treatment
Other Pre-specified Outcome Measures:
Title
Safety endpoints
Description
Number of patients with any of the following: Death or dependency (mRS 5-6) Symptomatic intracranial haemorrhage (sICH) at 30 (-/+ 6) hours (CT or MRI) as defined in Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), European Cooperative Acute Stroke Study (ECASS) II, National Institute of Neurological Disorders and Stroke (NINDS); Parenchymal hemorrhage type 2 (PH-2) Neurological deterioration within 7 days defined as an increase in NIHSS score by 4 or more points from baseline Adverse Events (AEs) Serious AEs (SAEs), Adverse Device Effects (ADEs), and Serious Adverse Device Effects (SADEs) including Unanticipated Adverse Device Effects (UADEs attributed to the stent retriever, reported in the interventional treatment arm Mortality rates at discharge and 90 days post-stroke Overall (all-cause mortality) death and stroke-related death Space-occupying infarction (malignant brain edema) New ischemic stroke
Time Frame
within 90 (+/- 14) days after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is ineligible for treatment with IV tPA according to licensing criteria (e.g. anticoagulation, previous surgery, or beyond 4.5 hours after symptom onset). Randomization within 7 hours after stroke onset. Endovascular treatment is expected to be finished within 8 hours after symptom onset by judgment of the interventional Neuroradiologist in charge. Patient must demonstrate clinical signs and symptoms attributable to target area of occlusion consistent with the diagnosis of ischemic stroke, including impairment of the following: language, motor function, sensation, cognition, gaze, and/or vision for at least 30 minutes without relevant improvement. Female and male patient between 18-80 years of age NIHSS Score of >7 and <25 Patient signed informed consent (IC) form by patient, legal representative, or by an independent physician who is familiar with this types of illness if the other options are not possible. A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or the intracranial segment of the distal internal carotid artery (ICA). Prior to new focal neurological deficit, mRS score was ≤1. Exclusion Criteria: Patient is eligible for and receives IV tPA according to licensing criteria Patient with an international normalized ratio (INR) of >3 Patient is an active participant in another drug or device treatment trial for any disease state, or patient is expected to start participation in another drug or device treatment trial while enrolled in this protocol, unless approved by Sponsor. Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations. Patient has carotid dissection, high grade stenosis ≥ 70% proximal to occlusion that requires stenting, or excessive tortuosity to gain access to occlusion, as determined by MRA/ CTA of neck and head. Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access) Patient has history of contraindication for contrast medium. Patient is known to have infective endocarditis CT scan or MRI with evidence of: Mass effect or intracranial tumor, or hypodensity on unenhanced CT and cerebral blood volume (CBV) drop on CBV maps on Computed Tomography Perfusion (CTP), or, alternatively as per institutional standard, restricted diffusion on Diffusion weighted imaging (DWI) with an Alberta Stroke Program Early CT score (ASPECTs) of 6 or less Female of childbearing potential who is known to be pregnant and/or lactating or who has a positive pregnancy test on admission. Patient"s anticipated life expectancy is less than 6 Months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Bendszus, MD
Organizational Affiliation
University Hospital Heidelberg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut für Radiologie Oö. Gesundheits- und Spitals-AG Landes-Nervenklinik Wagner-Jauregg
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Klinik für Diagnostische und Interventionelle Neuroradiologie Universitätsklinikum Aachen
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
Klinische und interventionelle Neuroradiologie Vivantes Klinikum Neukölln
City
Berlin
ZIP/Postal Code
12351
Country
Germany
Facility Name
Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin Universitätsklinikum Knappschaftskrankenhaus Bochum
City
Bochum
ZIP/Postal Code
44892
Country
Germany
Facility Name
University Clinic Bochum
City
Bochum
Country
Germany
Facility Name
Kinik für Radiologie und Neuroradiologie
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Facility Name
Abteilung für Neuroradiologie Universitätsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Klinik für Radiologie und Neuroradiologie Alfried Krupp Krankenhaus
City
Essen
ZIP/Postal Code
45131
Country
Germany
Facility Name
Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie Universitätsklinikum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Klinik für Neuroradiologie Universitätsklinikum Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Institut für Diagnostische & Interventionelle Neuroradiologie Universitätsmedizin Göttingen
City
Goettingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Asklepios Klinik Altona
City
Hamburg
ZIP/Postal Code
22763
Country
Germany
Facility Name
Universität Heidelberg, Neuroradiologie
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Diagnostik , Neuroradiologie, Universitätsklinikum Köln
City
Köln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Abteilung für Neuroradiologie Klinikum der Universität München Campus
City
München
ZIP/Postal Code
81377
Country
Germany
Facility Name
Abteilung für Diagnostische & Interventionelle Neuroradiogie Klinikum rechts der Isar der TU München
City
München
ZIP/Postal Code
81675
Country
Germany
Facility Name
Klinik für Radiologie, Neuroradiologie und Nuklearmedizin Behandlungszentrum Knappschaftskrankenhaus Recklinghausen
City
Recklinghausen
ZIP/Postal Code
45657
Country
Germany
Facility Name
Abteilung für Neuroradiologie Universitätsklinikum Würzburg
City
Würzburg
ZIP/Postal Code
97080
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
18388338
Citation
Kelly ME, Furlan AJ, Fiorella D. Recanalization of an acute middle cerebral artery occlusion using a self-expanding, reconstrainable, intracranial microstent as a temporary endovascular bypass. Stroke. 2008 Jun;39(6):1770-3. doi: 10.1161/STROKEAHA.107.506212. Epub 2008 Apr 3.
Results Reference
background
PubMed Identifier
22932714
Citation
Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012 Oct 6;380(9849):1231-40. doi: 10.1016/S0140-6736(12)61299-9. Epub 2012 Aug 26. Erratum In: Lancet. 2012 Oct 6;380(9849):1230.
Results Reference
background
PubMed Identifier
19590057
Citation
Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009 Aug;40(8):2761-8. doi: 10.1161/STROKEAHA.108.544957. Epub 2009 Jul 9.
Results Reference
background
PubMed Identifier
22932715
Citation
Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO; SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012 Oct 6;380(9849):1241-9. doi: 10.1016/S0140-6736(12)61384-1. Epub 2012 Aug 26.
Results Reference
background
PubMed Identifier
21852620
Citation
Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL; STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011 Sep;42(9):2645-50. doi: 10.1161/STROKEAHA.111.618850. Epub 2011 Aug 18.
Results Reference
background
PubMed Identifier
26275228
Citation
Kastner B, Behre S, Lutz N, Burger F, Luntz S, Hinderhofer K, Bendszus M, Hoffmann GF, Ries M. Clinical Research in Vulnerable Populations: Variability and Focus of Institutional Review Boards' Responses. PLoS One. 2015 Aug 14;10(8):e0135997. doi: 10.1371/journal.pone.0135997. eCollection 2015.
Results Reference
derived
PubMed Identifier
26044962
Citation
Bendszus M, Thomalla G, Knauth M, Hacke W, Bonekamp S, Fiehler J. Thrombectomy in patients ineligible for iv tPA (THRILL). Int J Stroke. 2015 Aug;10(6):950-5. doi: 10.1111/ijs.12527. Epub 2015 Jun 4.
Results Reference
derived

Learn more about this trial

Thrombectomy in Patients Ineligible for iv tPA

We'll reach out to this number within 24 hrs